(Q37766850)

22 August 2017

1 reference

title

Paliperidone extended release: a review of its use in the management of schizophrenia (English)

1 reference

22 August 2017

0 references

2

Gillian M Keating

1 reference

22 August 2017

Claudine M Chwieduk

1

1 reference

22 August 2017

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

70

1 reference

22 August 2017

10

1 reference

22 August 2017

1295-1317

1 reference

https://scigraph.springernature.com/pub.10.2165/11204840-000000000-00000

22 August 2017

0 references

cites work

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia

1 reference

12 December 2020

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

12 December 2020

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

1 reference

12 December 2020

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels

1 reference

12 December 2020

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

1 reference

12 December 2020

No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects

1 reference

12 December 2020

A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.

1 reference

12 December 2020

Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia

1 reference

12 December 2020

Antipsychotic drugs for first-episode schizophrenia: a comparative review

1 reference

12 December 2020

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

12 December 2020

Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

12 December 2020

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies

1 reference

12 December 2020

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension

1 reference

12 December 2020

Oral paliperidone for schizophrenia

1 reference

12 December 2020

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

1 reference

12 December 2020

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

1 reference

12 December 2020

Paliperidone: the evidence of its therapeutic value in schizophrenia

1 reference

12 December 2020

Paliperidone extended release

1 reference

12 December 2020

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study

1 reference

12 December 2020

A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.

1 reference

12 December 2020

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia

1 reference

12 December 2020

Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review

1 reference

12 December 2020

Limitations of current therapies: why do patients switch therapies?

1 reference

12 December 2020

Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis

1 reference

12 December 2020

The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.

1 reference

12 December 2020

What are the nursing implications when using paliperidone prolonged release for people with schizophrenia

1 reference

12 December 2020

How do we choose between atypical antipsychotics? The advantages of amisulpride

1 reference

12 December 2020

Paliperidone extended-release tablets: a new atypical antipsychotic

1 reference

12 December 2020

A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.

1 reference

12 December 2020

10.2165/11204840-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20568835

Dimensions Publication ID

22 August 2017

0 references

1 reference

PubMed ID

20568835